ABM Therapeutics, Inc. Report issue

For profit Phase 1
Founded: Hong Kong Hong Kong (2016)

Organization Overview

First Clinical Trial
2019
NCT04190628
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

ABM Therapeutics, Inc. | ABM Therapeutics Shanghai Company Limited

Active Ingredients

Drugs in Phase 1 Trials (1)

abm-1310 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 1